Does New Melanoma Data Redefine the Bull Case for Castle Biosciences' DecisionDx Platform (CSTL)? [Yahoo! Finance]
Castle Biosciences (NASDAQ:CSTL) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.
Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year [Yahoo! Finance]
Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year
New Data Confirms Performance of DecisionDx®-Melanoma to Identify Patients with Less Than Five Percent Risk of Sentinel Lymph Node Positivity [Yahoo! Finance]